Jonsson Comprehensive Cancer Center
🇺🇸United States
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1
Terminated
- Conditions
- Metastatic MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage III Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7
- Interventions
- Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503Other: Laboratory Biomarker AnalysisBiological: IpilimumabBiological: NivolumabOther: Pharmacological Study
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03425461
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer
Early Phase 1
Completed
- Conditions
- Stage I Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage III Breast Cancer AJCC v7Positive Axillary Lymph NodeStage IIB Breast Cancer AJCC v6 and v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7
- Interventions
- Device: Implanted Medical DeviceProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03411070
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
PET Imaging of the Immune System Using Analog Probes
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: [18F] CFA
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03409419
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib
- Conditions
- Progressive Metastatic Castrate Resistant Prostate Cancer
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT03386071
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
Not Applicable
Completed
- Conditions
- Stage III Prostate Cancer AJCC v7Prostate AdenocarcinomaStage IIB Prostate Cancer AJCC v7Stage IV Prostate Cancer AJCC v7
- Interventions
- Procedure: Computed TomographyRadiation: Gallium Ga 68 GozetotideProcedure: Positron Emission Tomography
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT03368547
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors
Not Applicable
Completed
- Conditions
- Stage II Breast Cancer AJCC v6 and v7Cancer SurvivorStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage 0 Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- Behavioral: Behavioral InterventionOther: Questionnaire Administration
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 133
- Registration Number
- NCT03319342
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California-Riverside, Riverside, California, United States
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Phase 1
Terminated
- Conditions
- HLA-A*0201 Positive Cells PresentSarcomaUnresectable Malignant NeoplasmLocally Advanced Malignant NeoplasmNY-ESO-1 Positive
- Interventions
- Other: 18F-FHBGBiological: AldesleukinBiological: Cellular TherapyProcedure: Computed TomographyBiological: FilgrastimProcedure: LeukapheresisProcedure: Positron Emission Tomography
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03240861
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
Not Applicable
Completed
- Conditions
- LesionBreast Neoplasm
- Interventions
- Device: Implanted Medical DeviceProcedure: MammographyOther: Questionnaire AdministrationProcedure: Radiofrequency (RFID) -Guided LocalizationProcedure: Ultrasonography
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03202472
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
Phase 1
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03148327
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne E., Victoria, Australia
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Phase 1
Terminated
- Conditions
- Invasive Breast CarcinomaStage II Breast CancerStage IIA Breast CancerEstrogen Receptor PositiveHER2/Neu NegativeMultifocal Breast CarcinomaPostmenopausalProgesterone Receptor PositiveStage I Breast CancerStage IA Breast Cancer
- Interventions
- Procedure: Biopsy of BreastOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03128619
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath